Synch’s Sara Sparring negotiated the license agreement between Lipidor AB (publ) and RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, in which exclusive rights was granted RELIFE S.r.l. to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries. The total potential value of this agreement is up to MEUR 70.
Ola Holmlund, CEO of Lipidor, says: “Lipidor is very pleased with our collaboration with Synch and Sara Sparring. Sara has a strong legal background combined with a pragmatic approach that helped us very much in long negotiations with several stake holders. Sara made herself fully available off hours to assist in discussions or to give valuable advice which was highly appreciated. All of this contributed fully to a successful agreement.”
Lipidor is a research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.
